Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2015-10-14 Director's Dealing
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 3 pages 40.5KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y Change of Director's Interest Notice filed with ASX, detailing a director's personal share transactions including the number of shares held before and after the transaction, the nature of the transaction (on-market trade), and relevant dates. It references Listing Rule 3.19A and the Corporations Act section 205G, which govern director shareholding disclosures. The document is short (4231 characters) and focuses solely on the director's share dealings without any financial results or company performance data. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades).
2015-10-14 English
Letter to Shareholders 2 pages 144.2KB
Management Reports Classification · 95% confidence The document is a letter dated 6 October 2015 addressed to shareholders from the Managing Director of Biotron Limited. It discusses interim data from a phase 2 clinical trial of the company's lead compound BIT225 for Hepatitis C virus (HCV). The letter explains the trial design, interim results for genotype 3 patients, and plans for future data releases and regulatory submissions. It is a detailed update on clinical trial progress and company outlook rather than a formal financial report or regulatory filing. The document does not contain financial statements, audit information, or formal voting results. It is not a transcript of a call, nor a capital or financing update. It is a communication to shareholders providing management commentary on clinical trial results and company strategy. This fits best with the category of Management Reports (MDA), which includes management's detailed explanation of business trends and outlook. The document length (5059 characters) and content support this classification rather than a brief announcement or a full annual/interim report.
2015-10-05 English
Presentation to Investors 10 pages 530.8KB
Investor Presentation Classification · 95% confidence The document is a presentation addressed to investors by Biotron Limited's Managing Director, containing detailed information about the company's drug development programs, clinical trial results, financial metrics, and strategic plans. It is explicitly described as a PowerPoint presentation presented to investors. The content includes forward-looking statements, clinical trial data, financial metrics, and company strategy, which are typical elements of an investor presentation. There is no indication that this is an official report like an annual or interim report, nor is it a brief announcement or certification. The document length (8697 characters) and detailed content support classification as an investor presentation rather than a short announcement or regulatory filing. Therefore, the most appropriate classification is Investor Presentation (IP).
2015-10-05 English
INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY 3 pages 33.6KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Biotron Limited dated 30 September 2015, providing interim data from a Phase 2 clinical trial (BIT225-008) involving Hepatitis C virus genotype 3 patients. It includes trial objectives, outcomes, safety and tolerability data, pharmacokinetic and antiviral efficacy results, and commentary from the Managing Director. The document is 9319 characters long, which is substantial and contains substantive data and analysis rather than just a brief announcement or a link to a report. It is not a full annual or quarterly financial report, nor is it a regulatory filing or certification. The content focuses on clinical trial interim results, which aligns with an Interim / Quarterly Report (IR) type, as it provides comprehensive data for a period shorter than a full fiscal year and includes substantive analysis and results. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q3 2015
2015-09-29 English
Annual Report to Shareholders 47 pages 362.9KB
Annual Report Classification · 100% confidence The document is a detailed report from Biotron Limited dated 28 August 2015, containing a Year End Accounts and Preliminary Final Report for the year ended 30 June 2015. It includes an Appendix 4E Preliminary Final Report, an audited Annual Report, Operating and Financial Review, Directors' Report, financial statements, and an Independent Auditor's Report. The content covers comprehensive financial performance, operating review, clinical trial progress, capital raising, and outlook for the next 12 months. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. The presence of the full Annual Report and detailed financial statements confirms this is the official yearly report covering company activity and full financial performance, consistent with the definition of an Annual Report (10-K). FY 2015
2015-08-27 English
Investor Presentation 15 pages 1.1MB
Investor Presentation Classification · 100% confidence The document is titled 'INVESTOR PRESENTATION' and is explicitly described as an updated Investor Presentation. It contains detailed slides about the company's drug development pipeline, clinical trial statuses, financial metrics, market opportunities, and strategic outlook. The content is typical of a presentation aimed at investors, focusing on business strategy, financial highlights, and product development rather than formal financial statements or regulatory disclosures. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document length (11,026 characters) supports a detailed presentation rather than a brief announcement. Therefore, the appropriate classification is Investor Presentation (IP).
2015-08-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.